Related Experiment Video
Updated: May 8, 2025
Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models
Published on: December 3, 2019
Serum ADAM17 levels pre-antiviral therapy correlate with HIV patient immune reconstitution
Ying Lin1, Ming Chen2, Xuelian Zhu3
1Department of Clinical Laboratory Medicine, Wenzhou Central Hospital, Dingli Clinical School of Wenzhou Medical University, Wenzhou, 325000, China.
Background:
The relationship between tumour necrosis factor (TNF) levels and disease progression is well-established. However, the impact of changes in the level of TNF hydrolase (A-disintegrin and metalloenzyme 17; ADAM17) in HIV patients remains to be fully elucidated.
Methods:
Between March 1 and December 31, 2017, data were collected from 64 HIV-positive individuals in Wenzhou. Based on their history of antiviral treatment at the time of enrollment, these patients were categorized into two cohorts: an antiviral-treated group and an untreated HIV group. Then, the serum ADAM17 levels of each group were measured and analysed.
Results:
In comparison to the antiviral-treated group and the control group, the untreated HIV group exhibited a significantly elevated serum ADAM17 level (p < 0.001). A significant negative correlation was observed between serum ADAM17 levels and CD4+ T cell counts in the untreated HIV group (r = -0.486, p = 0.001). ROC curve analysis revealed that the pre-treatment serum ADAM17 level in the untreated HIV group had moderate diagnostic accuracy for the AIDS stage (area under the curve: 0.703, p = 0.028). Additionally, serum ADAM17 levels were positively correlated with ADAM17 expression on the surface of leukocytes (r = 0.367, p = 0.018).
Conclusion:
Serum ADAM17 levels are significantly elevated in HIV patients and are correlated with disease progression and immune reconstitution.
